Journal
FRONTIERS IN MICROBIOLOGY
Volume 13, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fmicb.2022.987763
Keywords
gastric cancer; microbiota; immune checkpoint inhibitors; immune response; PD-L1; CTLA-4
Categories
Funding
- National Natural Science Foundation of China
- Precision Medicine Special project of Wuxi Municipal Health Commission
- Wuxi Administration of Traditional Chinese Medicine Scientific Research Project
- Top Talent Support Program for Young and Middle-Aged People of Wuxi Health Committee
- [82274269]
- [J201801]
- [ZYKJ201906]
Ask authors/readers for more resources
This paper reviews the relationship between microorganisms and gastric cancer, as well as the potential of combining microorganisms with immunotherapy to enhance immune response in gastric cancer patients.
Currently, conventional neoadjuvant therapy or postoperative adjuvant therapy, such as chemotherapy and radiation therapy, can only bring limited survival benefits to gastric cancer (GC). Median survival after palliative chemotherapy is also low, at about 8-10 months. Immunotargeting is a new option for the treatment of GC, but has not been widely replicated. The highly immunosuppressed tumor microenvironment (TME) discounts the efficacy of immunotherapy for GC. Therefore, new strategies are needed to enhance the immune response of the TME. This paper reviewed the relationship between microorganisms and GC, potential links between microorganisms and immunotherapy and research of microorganisms combined immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
